Promising new combo offers hope for aggressive lymphoma that stopped responding to treatment

This study tests a combination of three drugs (zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome) in about 26 adults with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this mix can shrink tumors and help people live longer without the cancer growing. Participants will receive up to 6 cycles of the combo, then up to 2 years of a single maintenance drug if they respond. The trial closely tracks both benefits and side effects.